Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. (abre nova janela)

Ball AM, Winstead PS.

Fonte‎: Pharmacotherapy 2008;28(11):1383-90.

Indexado‎: PubMed 18956998

DOI‎: 10.1592/phco.28.11.1383

https://www.ncbi.nlm.nih.gov/pubmed/18956998 (abre nova janela)

Severe acute anemia after liver transplantation in an elderly Jehovah's Witness treated with high-dose erythropoietin and ferric carboxymaltose: a case report. (abre nova janela)

Brunetta DM, Kaufman J, De Santis GC, Mesquita DF, Souza FN, Garcia JH.

Fonte‎: Transplant Proc 2015;47(8):2548-51.

Indexado‎: PubMed 26518969

DOI‎: 10.1016/j.transproceed.2015.09.014

https://www.ncbi.nlm.nih.gov/pubmed/26518969 (abre nova janela)

Recombinant human erythropoietin in severe anaemia: issues of dosing and duration. (abre nova janela)

Charles A, Purtill M, Napolitano LM.

Fonte‎: Anaesth Intensive Care 2006;34(6):793-6.

Indexado‎: PubMed 17183900

https://www.ncbi.nlm.nih.gov/pubmed/17183900 (abre nova janela)

Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. (abre nova janela)

Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ.

Fonte‎: Crit Care Med 1999;27(11):2346-50.

Indexado‎: PubMed 10579246

https://www.ncbi.nlm.nih.gov/pubmed/10579246 (abre nova janela)

The role of erythropoietin therapy in the critically ill. (abre nova janela)

Corwin HL.

Fonte‎: Transfus Med Rev 2006;20(1):27-33.

Indexado‎: PubMed 16373185

DOI‎: 10.1016/j.tmrv.2005.08.002

https://www.ncbi.nlm.nih.gov/pubmed/16373185 (abre nova janela)

Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. (abre nova janela)

Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A; Critical Care Clinical Trials Greek Group.

Fonte‎: Crit Care 2005;9(5):R508-15.

Indexado‎: PubMed 16277712

DOI‎: 10.1186/cc3786

https://www.ncbi.nlm.nih.gov/pubmed/16277712 (abre nova janela)

Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. (abre nova janela)

Khalafallah AA, Yan C, Al-Badri R, Robinson E, Kirkby BE, Ingram E, Gray Z, Khelgi V, Robertson IK, Kirkby BP.

Fonte‎: Lancet Haematol 2016;3(9):e415-25.

Indexado‎: PubMed 27570088

DOI‎: 10.1016/S2352-3026(16)30078-3

https://www.ncbi.nlm.nih.gov/pubmed/27570088 (abre nova janela)

Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. (abre nova janela)

Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H.

Fonte‎: Intensive Care Med 2013;39(11):1896-908.

Indexado‎: PubMed 23928897

DOI‎: 10.1007/s00134-013-3030-9

https://www.ncbi.nlm.nih.gov/pubmed/23928897 (abre nova janela)

An international consensus statement on the management of postoperative anaemia after major surgical procedures. (abre nova janela)

Muñoz M, Acheson AG, Bisbe E, Butcher A, Gómez-Ramírez S, Khalafallah AA, Kehlet H, Kietaibl S, Liumbruno GM, Meybohm P, Rao Baikady R, Shander A, So-Osman C, Spahn DR, Klein AA

Fonte‎: Anaesthesia 2018;73(11):1418-31.

Indexado‎: PubMed 30062700

DOI‎: 10.1111/anae.14358

https://www.ncbi.nlm.nih.gov/pubmed/30062700 (abre nova janela)

How do we treat life-threatening anemia in a Jehovah's Witness patient? (abre nova janela)

Posluszny JA Jr, Napolitano LM.

Fonte‎: Transfusion 2014;54(12):3026-34.

Indexado‎: PubMed 25330835

DOI‎: 10.1111/trf.12888

https://www.ncbi.nlm.nih.gov/pubmed/25330835 (abre nova janela)

Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery. (abre nova janela)

Price S, Pepper JR, Jaggar SI.

Fonte‎: Anesth Analg 2005;101(2):325-7.

Indexado‎: PubMed 16037136

DOI‎: 10.1213/01.ANE.0000159158.70532.D0

https://www.ncbi.nlm.nih.gov/pubmed/16037136 (abre nova janela)

Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. (abre nova janela)

Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A; Surgical Clinical Outcome REsearch (SCORE) Group.

Fonte‎: J Am Heart Assoc 2015;4(6):e002066.

Indexado‎: PubMed 26037084

DOI‎: 10.1161/JAHA.115.002066

https://www.ncbi.nlm.nih.gov/pubmed/26037084 (abre nova janela)

Life-threatening postoperative blood loss in a Jehovah's Witness, treated with high-dose erythropoietin. (abre nova janela)

Schälte G, Janz H, Busse J, Jovanovic V, Rossaint R, Kuhlen R.

Fonte‎: Br J Anaesth 2005;94(4):442-4.

Indexado‎: PubMed 15653706

DOI‎: 10.1093/bja/aei068

https://www.ncbi.nlm.nih.gov/pubmed/15653706 (abre nova janela)

Transfusion-free management of gastrointestinal bleeding: the experience of a Bloodless Institute. (abre nova janela)

Sharma P, Barajas FJ, Krishnamoorthy P, Campo LM, Blumenthal E, Spinnell M.

Fonte‎: J Clin Gastroenterol 2015;49(3):206-11.

Indexado‎: PubMed 25144897

DOI‎: 10.1097/MCG.0000000000000200

https://www.ncbi.nlm.nih.gov/pubmed/25144897 (abre nova janela)

Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. (abre nova janela)

Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL.

Fonte‎: Crit Care Med 2006;34(9):2310-6.

Indexado‎: PubMed 16878035

DOI‎: 10.1097/01.CCM.0000233873.17954.42

https://www.ncbi.nlm.nih.gov/pubmed/16878035 (abre nova janela)